Review our latest corporate presentation with an overview of company highlights, recent milestones and clinical updates.
Downloads
Investor Presentation
SITC 2024 Poster – TUSC2 Modulates Cancer Immune Responses
Reqorsa® Gene Therapy Modulates In Vivo Immune Responses Against Cancer
EROTC-NCI-AACR 2024 Poster – TUSC2 Gene Therapy in KRASG12C Mutant NSCLC Overcomes Acquired Resistance to Sotorasib
Reqorsa® Gene Therapy Overcomes Acquired Resistance to Lumakras® in Lung Cancer
EROTC-NCI-AACR 2024 Poster – TUSC2 Suppresses Tumorigenic Properties in Malignant Pleural Mesothelioma Cells
Reqorsa® Gene Therapy Demonstrated Potent Tumor Suppressive Activity in Mesothelioma
EROTC-NCI-AACR 2024 Poster – Efficacy of Quaratusugene Ozeplasmid (REQORSA) TUSC2 Gene Therapy in Glioblastoma
Reqorsa® Gene Therapy Induces Apoptosis in Glioblastoma
2024 AACR Poster – Quaratusugene ozeplasmid mediated TUSC2 upregulation in EML4-ALK bearing Non-Small Cell Lung Carcinoma can induce cellular apoptosis
Reqorsa® Gene Therapy May be a Potential Therapy for ALK-Positive Lung Cancer
2024 AACR Poster – Mechanism of NPRL2 gene therapy induced anti-tumor immunity in KRAS/STK11mt aPD1 resistant metastatic NSCLC
NPRL2 Gene Therapy Induces Effective Anti-Tumor Immunity in Non-Small Cell Lung Cancer Humanized Mouse Model
2024 AACR Poster – Tumor Suppressor Gene TUSC2 suppresses energy metabolism in lung cancer cells with opposite effects in normal bronchial epithelial cells
REQORSA has Anti-Tumor Mechanisms that Target and Disrupt the Metabolism of Cancer Cells
AACR-NCI-EORTC International Conference 2023 – Completion of Acclaim-1 Dose Escalation: Recommended Phase 2 Dose of Quaratusugene Ozeplasmid Gene Therapy and Osimertinib
Acclaim-1 Phase 1 study had no Dose Limiting Toxicity, and results establish Phase 2 Recommended Dose as well as provide data showing efficacy of REQORSA® in combination with Tagrisso®
AACR-NCI-EORTC International Conference 2023 – TUSC2 immunogene therapy enhances checkpoint blockade through increased cytotoxic immune activation in chemo-resistant small cell lung cancer (SCLC) in humanized mice
Preclinical results show that REQORSA® in combination with a checkpoint inhibitor has anti-tumor activity in a humanized mouse model of small cell lung cancer (SCLC)
2023 AACR Abstract – NPRL2 gene therapy induces effective antitumor immunity in KRAS/STK11 mutant anti-PD1 resistant metastatic human NSCLC in a humanized mouse model
The abstract reports NPRL2 gene therapy induces effective anti-tumor activity in non-small cell lung cancer pembrolizumab resistant tumors in a humanized mouse model and provides preclinical validation of the ONCOPREX® Nanoparticle Delivery System with a second tumor suppressor gene
ATTD 2023 – Pancreatic Intraductal Infusion of Adeno-Associated Virus To Treat Non- Human Primates in a Toxin-Induced Diabetes Model
Data highlighting the potential of Genprex’s gene therapy for Type 1 diabetes was being presented by its research collaborators at the University of Pittsburgh at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) on February 25, 2023 in Berlin, Germany.
Fact Sheet
A one-page fact sheet and overview of Genprex.
TUSC2 Bibliography
A bibliography of selected publications describing the TUSC2 gene.
PDX1 and MAFA Bibliography
A bibliography of selected publications describing the PDX1 and MAFA genes.
2021 AACR Poster – Overcoming resistance to osimertinib by TUSC2 gene therapy in EGFR mutant NSCLC – Meraz
The poster presents positive preclinical data for REQORSA in combination with Tagrisso®, demonstrating synergistic antitumor efficacy in EGFR mutant Tagrisso resistant NSCLC tumors in H1975-OsiR isogenic tumors. Researchers also found that the upregulation of PDK1 was associated with osimertinib resistance.
2020 International Journal of Molecular Sciences
The study found TUSC2 may be a novel target and biomarker for thyroid cancer therapy.
2019 AACR KRAS and LKB1 Poster – Meraz
The poster demonstrates research and data on the efficacy of novel immunogene combinations for KRAS and LKB1 mutant NSCLC in a humanized mouse model.
2019 Nature Research Scientific Reports
The study found that TUSC2 prevented tumor growth in triple-negative breast cancer (TNBC), which is currently considered an incurable cancer with limited therapeutic options.
2019 AACR Hu-PDX Poster – Meraz
The poster presents positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer in a humanized mouse model.
Designed and Secured by Barsec